Humanized IgG1 monoclonal antibody against GD2

DRUG3 trials

Sponsors

Y-mAbs Therapeutics A/S, Instytut Matki I Dziecka, Fundacio Sant Joan De Deu

Conditions

Ewing's sarcomaNeuroblastoma or ganglioneuroblastoma (nodular or intermixed)Treatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

Phase 2

A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

RecruitingCTIS2023-508587-29-00

Y-mAbs Therapeutics A/STreatment of high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow

Start: 2018-04-03Target: 81Updated: 2025-11-04

To evaluate the efficacy and safety of naxitamab in patients with refractory Ewing's sarcoma.

RecruitingCTIS2024-514441-11-00

Instytut Matki I DzieckaEwing's sarcoma

Start: 2023-09-28Target: 24Updated: 2024-08-06

A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma

Not yet recruitingCTIS2025-524140-35-00

Fundacio Sant Joan De DeuNeuroblastoma or ganglioneuroblastoma (nodular or intermixed)

Target: 22Updated: 2026-05-19